Stryker Buys Target Neurovascular Biz From Boston Scientific For $1.5 Billion
This article was originally published in The Gray Sheet
Stryker will enter the neurovascular market and become segment leader through the $1.5 billion purchase of Target Therapeutics from Boston Scientific, the firms announced Oct. 28.
You may also be interested in...
Purchase of Surpass Medical for $135 million represents Stryker’s 10th acquisition since 2009. The company affirmed its acquisition strategy focused on core and key adjacent markets during its Oct. 17 earnings call, but also sought to ratchet down earnings growth expectations in the near term to account for headwinds, including the upcoming U.S. medical device excise tax.
Agency restricts use of the device to a select patient population with severe intracranial stenosis and recurrent stroke after reviewing studies indicating the device could actually lead to increased rates of stroke and death.
While some companies have started to reveal strategies to either soften the blow or to capitalize on the impending device excise tax, many have revealed little to no detail on their planned response.